PerspectiveNeuroscience

Insulin Signaling in Sporadic Alzheimer’s Disease

Sci. Signal.  09 Jun 2009:
Vol. 2, Issue 74, pp. pe36
DOI: 10.1126/scisignal.274pe36

You are currently viewing the abstract.

View Full Text

Via your Institution

Log in through your institution

Log in through your institution


Abstract

Excessive production of β-amyloid (Aβ) peptides from proteolytic cleavage of amyloid precursor protein is believed to play a central role in the pathogenesis of Alzheimer’s disease (AD). In particular, accumulated intracellular Aβ is found in vulnerable neurons, and the soluble oligomers of Aβ peptides [also termed Aβ-derived diffusible ligands (ADDLs)] are highly toxic to neurons. Evidence shows that both extracellular and intracellular ADDLs can compromise insulin signaling. Extracellular ADDLs can bind to synapses and decrease membrane insulin receptors (IRs) through an insulin signaling–dependent mechanism. Intracellular Aβ inhibits IR signaling in neurons by interfering with the association between phosphoinositide-dependent kinase 1 and Akt1 to preclude Akt1 activation. Together, these findings suggest that agents that stimulate insulin signaling may have neuroprotective effects. Indeed, insulin and insulin sensitizers have been shown to improve cognitive and memory functions in animal models of AD, as well as in AD patients.

View Full Text

Related Content